Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer

• Published in: JAMA oncology Vol. 4; no. 3; p. 351
• Main Authors: Mezquita, Laura, Auclin, Edouard, Ferrara, Roberto, Charrier, Melinda, Remon, Jordi, Planchard, David, Ponce, Santiago, Ares, Luis Paz, Leroy, Laura, Audigier-Valette, Clarisse, Felip, Enriqueta, Zerón-Medina, Jorge, Garrido, Pilar, Brosseau, Solenn, Zalcman, Gérard, Mazieres, Julien, Caramela, Caroline, Lahmar, Jihene, Adam, Julien, Chaput, Nathalie, Soria, Jean Charles, Besse, Benjamin
• Format: Journal Article
• Language: English
• Published: United States 01-03-2018
• Subjects: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor - analysis; Biomarkers, Tumor - immunology; Carcinoma, Non-Small-Cell Lung - diagnosis; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - immunology; Carcinoma, Non-Small-Cell Lung - pathology; Cell Cycle Checkpoints - drug effects; Cell Cycle Checkpoints - immunology; Disease Progression; Female; Health Status Indicators; Humans; Lung - drug effects; Lung - immunology; Lung - pathology; Lung Neoplasms - diagnosis; Lung Neoplasms - drug therapy; Lung Neoplasms - immunology; Lung Neoplasms - pathology; Male; Middle Aged; Prognosis; Protein Kinase Inhibitors - therapeutic use; Retrospective Studies; Treatment Outcome; Tumor Microenvironment - drug effects; Tumor Microenvironment - immunology
• ISSN: 2374-2445
• DOI: 10.1001/jamaoncol.2017.4771

Derived neutrophils/(leukocytes minus neutrophils) ratio (dNLR) and lactate dehydrogenase (LDH) level have been correlated with immune checkpoint inhibitor (ICI) outcomes in patients with melanoma.
To determine whether pretreatment dNLR and LDH are associated with resistance to ICIs in patients with advanced non-small cell lung cancer (NSCLC).
Multicenter retrospective study with a test (n = 161) and a validation set (n = 305) treated with programmed death 1/programmed death ligand 1 (PD-1/PD-L1) inhibitors in 8 European centers, and a control cohort (n = 162) treated with chemotherapy only. Complete blood cell counts, LDH, and albumin levels were measured before ICI treatment. A lung immune prognostic index (LIPI) based on dNLR greater than 3 and LDH greater than upper limit of normal (ULN) was developed, characterizing 3 groups (good, 0 factors; intermediate, 1 factor; poor, 2 factors).
The primary end point was overall survival (OS). Secondary end points were progression-free survival (PFS) and disease control rate (DCR).
In the pooled ICI cohort (N = 466), 301 patients (65%) were male, 422 (90%) were current or former smokers, and 401 (87%) had performance status of 1 or less; median age at diagnosis was 62 (range, 29-86) years; 270 (58%) had adenocarcinoma and 159 (34%) had squamous histologic subtype. Among 129 patients with PD-L1 data, 96 (74%) had PD-L1 of at least 1% by immunohistochemical analysis, and 33 (26%) had negative results. In the test cohort, median PFS and OS were 3 (95% CI, 2-4) and 10 (95% CI, 8-13) months, respectively. A dNLR greater than 3 and LDH greater than ULN were independently associated with OS (hazard ratio [HR] 2.22; 95% CI, 1.23-4.01 and HR, 2.51; 95% CI, 1.32-4.76, respectively). Median OS for poor, intermediate, and good LIPI was 3 months (95% CI, 1 month to not reached [NR]), 10 months (95% CI, 8 months to NR), and 34 months (95% CI, 17 months to NR), respectively, and median PFS was 2.0 (95% CI, 1.7-4.0), 3.7 (95% CI, 3.0-4.8), and 6.3 (95% CI, 5.0-8.0) months (both P < .001). Disease control rate was also correlated with dNLR greater than 3 and LDH greater than ULN. Results were reproducible in the ICI validation cohort for OS, PFS, and DCR, but were nonsignificant in the chemotherapy cohort.
Pretreatment LIPI, combining dNLR greater than 3 and LDH greater than ULN, was correlated with worse outcomes for ICI, but not for chemotherapy, suggesting that LIPI can serve as a potentially useful tool when selecting ICI treatment, raising the hypothesis that the LIPI might be useful for identifying patients unlikely to benefit from treatment with an ICI.